Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.
Zhang Q, Zhu X, Liu B, Zhang Y, Xiao Y. Zhang Q, et al. Among authors: xiao y. Front Immunol. 2023 Mar 17;14:1127868. doi: 10.3389/fimmu.2023.1127868. eCollection 2023. Front Immunol. 2023. PMID: 37006273 Free PMC article.
Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy.
Shang Z, Zhang Q, Liu W, Wu J, Zhang Y, Xiao Y. Shang Z, et al. Among authors: xiao y. Front Oncol. 2023 Oct 2;13:1242552. doi: 10.3389/fonc.2023.1242552. eCollection 2023. Front Oncol. 2023. PMID: 37849796 Free PMC article.
Upper gastrointestinal tract immune-related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell transplantation for refractory/relapsed diffuse large B cell lymphoma.
Zhang Q, Li C, Cao Y, Wang N, Huang L, Shang Z, Wang J, Huang L, Xu J, Xiao M, Chen L, Zhu X, Zhang Y, Xiao Y. Zhang Q, et al. Among authors: xiao y, xiao m. Clin Case Rep. 2024 Jan 17;12(1):e8411. doi: 10.1002/ccr3.8411. eCollection 2024 Jan. Clin Case Rep. 2024. PMID: 38235413 Free PMC article.
Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W, Wu J, Ming X, Zhang Q, Zhou D, Zheng R, Zhou M, Shang Z, Chen L, Zhu X, Xiao Y. Liu W, et al. Among authors: xiao y. Front Immunol. 2024 Feb 5;15:1346001. doi: 10.3389/fimmu.2024.1346001. eCollection 2024. Front Immunol. 2024. PMID: 38375471 Free PMC article.
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X, Lin L, Yang Y, Wang N, Wang J, Xu J, Wei J, Huang L, Zheng M, Xiao Y, Meng F, Cao Y, Zhu X, Zhang Y. Xin X, et al. Among authors: xiao y. Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19. Cytotherapy. 2024. PMID: 38385909 Free article.
20,650 results
You have reached the last available page of results. Please see the User Guide for more information.